Unstable carotid plaque characteristics increase between 2010-2021 in carotid endarterectomy patients

Tetiana Motsak[a,b*], Barend Mol[a*], Joost Hoekstra[a,c], Gerard Pasterkamp[d], Gert J de Borst[a], Dominique PV de Kleijn[a]

a Dept of Vascular Surgery, UMC Utrecht, the Netherlands
b Dept Internal Medicine, Bogomolets National Medical University, Kyiv,Ukraine
c Dept of Nephrology, UMC Utrecht, the Netherlands
d Central Diagnostic Laboratory, UMC Utrecht, the Netherlands
*Barend Mol & Tetiana Motsak contributed equally

Abstract

Background:
Over the past decades, carotid plaque characteristics have been studied in association with previous symptoms and future cardiovascular events. We showed that destabilizing atherosclerotic plaque characteristics in carotid atherectomy patients between 2002 -2011 were decreasing. Time-dependent changes in plaque composition in the last decade, however, have not been studied. In this study, we investigate carotid plaque characteristics in carotid endarterectomy patients over the last decade.

Methods: Atherosclerotic plaques from 1,362 carotid endarterectomy patients included in the Athero-Express biobank between 2010 and 2021 were analyzed to examine time dependent changes in histological plaque characteristics in intervals of 2 years. These results were compared with our previous time dependent plaque composition data between 2002-2011.

Results: In contrast to the period 2002-2011 where vulnerable plaque characteristics were decreasing, the period 2010-2021 showed significant increase in vulnerable plaque characteristics: large lipid cores, intraplaque hemorrhage, macrophages, and calcification. When adjusted for confounders related to these plaque characteristics, such as time to operation and pre-operative symptoms, the adjusted odds ratios per 2 years increase in time were 1,177 (95% confidence interval, 1,070-1,293; $p<0,001$) for calcification, 1,352 (95% confidence interval, 1,229-1,487; $p<0,000$) for intraplaque hemorrhage, 1,277 (95% confidence interval, 1,159-1,407; $p<0,000$) for plaques consisting of >40% of fat and 1,388 (95% confidence interval, 1,262-1,528; $p<0,000$) for macrophages.

Conclusion:
Our study shows an increase in plaque characteristics associated with plaque vulnerability in 2010-2021 despite an overall decrease in cardiovascular mortality in Western Europe.

Keywords: Plaque vulnerability, Atherosclerosis, Carotid endarterectomy, Time dependent changes

Introduction

Atherosclerosis is the underlying cause of cardiovascular events like myocardial infarction and stroke with atherosclerotic plaques developing over decades in human life. Atherosclerotic plaque progression can lead to the formation of complex lesions with a large lipid core, thin fibrous cap, high influx of macrophages and intraplaque hemorrhage. These complex lesions can, upon rupture or erosion, result in atherosclerotic cardiovascular disease (ASCVD) related events such as ischemic stroke or myocardial infarction. (1,2) The carotid artery is one of the main atherosclerotic sites where such developments can lead to clinical events. (3–5). While the degree of carotid stenosis is a significant risk factor, the composition of these plaques has independently been associated with accelerated plaque progression, poorer clinical outcomes and can provide additional insights for risk assessment. (1,6–9)

World-wide incidence and mortality of cardiovascular disease is increasing in the last 3 decades (1990-2019) but with large regional differences. (10) In Western Europe, a large decrease in cardiovascular mortality occurs with minor or no changes in incidence. (10) Similar results were found in a large UK study (1980-2013) were prevalence remained unchanged and a declined CVD mortality was found together with an increase in hospital admission and CVD prescriptions. (11)
Much more recently (2006-2019) the SWEDEHEART registry, a large study on myocardial infarction patients, showed that proportion of patients attaining the targets for blood pressure and LDL-C increased significantly. (12) This registry, however, also showed that in the last decade, that central obesity, diabetes and patients reporting inadequate levels of physical activity also increased. (12)

With the decrease in CVD mortality in Western-Europe in the background, time-dependent changes in atherosclerotic plaque characteristics were studied in carotid atherectomy patients between 2002 - 2011 (13). This revealed that carotid atherosclerotic plaques showed a time-dependent change in plaque composition characterized by a decrease in destabilizing plaque characteristics like plaque thrombosis, plaque atheroma, plaque calcification and plaque macrophages. (13) This is in line with decreased mortality and increased CVD prescriptions. (10,11) Time-dependent changes in plaque composition in the last decade, however, have not been studied yet despite an increase in diabetes and obesity and less physical activity. (12)

In this study, we again used carotid plaque histology collected in the Athero-Express biobank (14) to study the change in plaque composition between 2010-2021 and compared it with our previous time dependent plaque composition data between 2002-2011.

Methods

Athero-Express

Study Population

For this study, atherosclerotic plaques from the Athero Express biobank were used. The Athero Express biobank is an ongoing, longitudinal biobank study and collects atherosclerotic plaques and plasma of both carotid- and femoral endarterectomy patients. An extensive study design has been published earlier. (14). Written informed consent was obtained from all included patients and the medical ethics committees of both the University Medical Center Utrecht and St Antonius Hospital Nieuwegein approved the study. For patients included from 2002 to 2011, data was used from the publication of Guus W. van Lammeren (13). New data was included in this study from patients included in the Athero Express between 2010 up to 2021 who underwent carotid endarterectomy. Patients were excluded from the study if informed consent was lacking. Indication for surgery was based on international guidelines for symptomatic and asymptomatic carotid stenosis (15,16) . All indications were reviewed by a multidisciplinary team of vascular specialists before surgery. Patient data were obtained via standardized questionnaires and preoperative admission charts.

Plaque Processing and Assessment

Atherosclerotic plaques of patients were harvested during carotid endarterectomy according to a standardized and previously reported protocol. (14,17) Briefly, carotid plaques were divided into segments of 5-mm thickness. The section with the largest plaque burden was classified as the culprit lesion and subjected to immunohistochemical staining. Macrophages, smooth muscle cells (SMC), thrombus, collagen, and calcifications were scored semi-quantitatively at a x40 magnification, according to the following criteria: no (1) or minor (2) staining along part of the luminal border of the plaque or a few scattered spots within the lesion; moderate (3) or heavy (4) staining was scored when along the entire luminal border or evident parts within the lesion staining was present. These categories were grouped into no/minor and moderate/heavy for trend descriptions and logistic regression analyses. Size of the lipid core was, as was previously done, visually assessed using polarized light with a cut off at 40% of the plaque area. Intraplaque hemorrhage was defined as any thrombus staining. All of the histologic scorings were performed by the same dedicated technician during the entire study period.

Definitions of Risk Factors and Medical Treatment

For baseline characteristics, all patients were asked to complete an extensive questionnaire which was checked with medical records. Height and length were measured before surgery in the outpatient clinic to calculate the BMI. Blood withdrawal was performed at baseline to assess creatinine level, which was used to calculate the estimated glomerular filtration rate with the Modification of Diet in Renal Disease formula (MDRD) (18). Patients were considered smokers if they reported to be smoking until the year of inclusion. Diabetes mellitus was restricted to those patients receiving medical treatment including insulin or oral glucose-lowering drugs. All medication was registered at baseline, including statins, use of antihypertensive drugs including β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, and diuretics. Furthermore, prescription of antithrombotic and anticoagulant medication was registered. Patients undergoing carotid endarterectomy, the index event was registered as transient ischemic attack, stroke, or ocular symptoms (including amaurosis fugax or retinal infarction) or alternatively as asymptomatic if no neurological symptoms were present within 6 months of the operation. In addition, the time interval between the last symptomatic event and surgery was registered.

Follow-Up and Outcome

Patients included in the Athero-Express study were asked to fill in a follow-up questionnaire after 1, 2, and 3 years regarding potential cardiovascular events. If the questionnaire was answered positively, further research was performed to investigate the potential outcome of the event. If the patient did not respond, the general practitioner was contacted if patient gave their consent on their informed consent form. The composite end point included any death of presumed vascular origin (stroke, myocardial infarction, sudden death, or other vascular death), ischemic stroke and myocardial infarction.

Statistical Analyses

All data from 2002 up to 2011 was used from the publication of Guus W. van Lammeren (13). To investigate time trends with sufficient sample sizes in different time periods, we studied plaque and patient characteristics over 2-year intervals from 2010 to 2021. To compare baseline and plaque characteristics over time, Pearson's Chi-squared tests, Fisher's exact test and Kruskal-Wallis rank sum test were performed when applicable. To compare variables between the entire 2002 – 2011 and 2010 – 2021 periods, Mann-Whitney U Tests and Chi-square tests were used when applicable. To assess changes in time for histological plaque characteristics, a logistic regression analysis was performed. To correct for potential confounders, the multivariate logistic regression analysis was corrected for baseline characteristics with incomparability over time (*p*-value for selection <0.20). For this analysis, plaque characteristics were dichotomized. For macrophages, calcification, smooth muscle cells and collagen into no/minor and moderate/heavy staining. Fat was binned below or above 40% of plaque volume and intraplaque hemorrhage either as present or absent. Two sided p-values of <0.05 were considered statistically significant and all statistical analyses were performed with RStudio version 4.2.1. (R Foundation, Vienna, Austria).

<div align="center">

Results

</div>

Patients

To investigate if patients undergoing carotid endarterectomy are different within the period 2010-2021 and 2002-2011 we compared baseline patient characteristics including medication and plaque characteristics over both periods. This was summarized in 2 tables (Table 1 baseline characteristics and medication; Table 2 plaque characteristics) that includes both periods (2002-2021 (period 2002-2011 and 2010-2021)

Patients characteristics

Patients characteristics in the total period of 2002-2021 undergoing endarterectomy are shown in Table 1. Data and p-values from 2002-2011 were as previously published (13) and data and p-values from 2010-2021 were added. Age at the time of surgery was increased between 2002 through 2011 (p<0.001) while age did not differ between 2010 through 2021. Sex was not significantly different over time in both periods while percentage of active smoking patients was decreased between 2002-2011 and did not change between 2010-2021. Percentage of diabetes and BMI did not change over time in both periods. Mean eGFR was increasing in 2010-21 from 73.1 in 2010-11 to 79.3 in 2020-21. Mean eGFR was higher in 2010-21 compared with 2002-2011 (78.8 vs 72.0, p<0.001). Median time between last event and surgery was decreasing in both periods: 111 days in 2002 through 2003, 20 days in 2010 through 2011 and 13 days in 2020 through 2021. Median time to event was shorter in 2010-21 compared to 2002-11 (15 days vs 39 days in 2002-11, p<0.001). The mean percentage of asymptomatic patients was decreasing from 2002 – 2011 to 2010-2021 (14.5% vs 10.7%, p=0.002) while the mean percentage of stroke patients was higher in 2010-21 compared to 2002-2011 (30.1% vs 26.0%, p=0.013). Peripheral arterial occlusive disease (PAOD), hypertension and history of Coronary Artery Disease (CAD) did not change over time in both periods.

Table 1. Patient Characteristics Over Time

Patient characteristic	2002-2003 (n=250)	2004-2005 (n=408)	2006-2007 (n=352)	2008-2009 (n=332)	2010-2011 (n=318)	2012-2013 (n=317)	2014-2015 (n=238)	2016-2017 (n=150)	2018-2019 (n=130)	2020-2021 (n=121)	p-value 2002-2011	p-value 2010-2021
Age – mean (SD)	66.4 (8.50)	68.3 (9.3)	68.7 (9.2)	69.7 (8.9)	69.6 (10.0)	70.2 (8.9)	70.3 (9.2)	71.4 (9.0)	71.2 (8.7)	70.8 (9.3)	<0.001	0.473
Sex, male (%)	69.2	70.3	67.9	67.2	67.6	68.5	70.6	73.3	68.4	67.8	0.357	0.845
Current smoking (%)	45.6	33.1	33.8	30.4	32.8	34.2	31.1	31.5	35.1	28.9	0.003	0.882
Diabetes Mellitus (%)	21.2	22.1	25.6	19.3	26.1	23.7	23.1	27.3	29.3	15.1	0.893	0.117
eGFR (SD)	71.5 (18.6)	70.3 (19.8)	72.7 (22.8)	71.3 (20.2)	73.1 (20.3)	73.9 (21.2)	77.6 (24.0)	76.9 (23.8)	79.7 (24.8)	79.3 (23.5)	0.157	0.042
BMI (SD)	26.4 (3.8)	26.2 (3.9)	26.5 (3.7)	26.1 (3.4)	26.7 (4.6)	26.2 (3.9)	26.9 (4.6)	26.9 (4.4)	26.9 (4.9)	26.3 (5.1)	0.525	0.351
Time between last event and surgery (days) (IQR)	111 (54;159)	65 (26;121)	44 (18;72)	30 (13;53)	20 (11;36)	14 (10;26)	14 (9; 21)	12 (8; 20)	14 (9;26)	13 (9;20)	<0.001	<0.001
Pre-operative symptoms											<0.001	0.024
Asymptomatic (%)	21.2	17.2	13.9	10.8	10.4	9.9	12.2	10.7	7.5	13.7		
Ocular (%)	14.8	12.5	14.8	16.9	18.0	19.4	22.4	16.7	33.8	29.9		
TIA (%)	40.0	45.3	50.9	44.6	41.1	39.5	35.9	36.7	33.8	29.9		
Stroke (%)	24.0	25.0	20.5	27.7	30.4	31.2	29.5	36.0	24.8	26.5		
Hypertension, (%)	82.5	89.7	86.1	88.5	82.1	87.1	82.7	78.7	87.2	78.2	0.010	0.086
History of PAOD (%)	26.0	19.6	19.3	22.0	21.1	24.3	16.5	22.7	20.3	19.3	0.115	0.356
History of CAD (%)	37.2	28.7	31.5	30.7	32.7	30.9	29.1	38.9	30.8	24.4	0.188	0.184
Statin use (%)	64.8	73.3	81.2	78.6	82.1	82.0	84.8	86.6	77.1	92.2	<0.001	0.027
β-Blocker use (%)	46.0	47.5	44.3	46.7	39.3	38.9	41.4	36.9	45.5	33.6	0.417	0.488
ACE-inhibitor use (%)	30.0	34.1	33.0	26.8	32.7	30.1	28.3	33.6	36.4	26.7	0.707	0.469
ARB use (%)	18.4	18.1	22.2	24.1	25.2	22.2	24.9	16.8	18.2	22.4	0.004	0.277
Diuretic use (%)	31.2	35.0	35.8	38.3	35.8	35.4	33.8	29.5	32.6	31.0	0.388	0.750
Antiplatelet use (%)	87.6	85.5	84.4	83.7	89.0	88.9	86.1	82.6	76.5	85.5	0.289	0.007
Anticoagulant use (%)	14.4	11.8	13.6	12.0	10.1	9.2	10.1	7.4	6.4	12.6	0.137	0.598

Table 1. Characteristics of patients undergoing carotid endarterectomy and included in the longitudinal biobank study Athero-Express 2002 – 2021 years. Data and p-values from 2002-2011 were as previously published by van Lammeren etal (Circulation, 2014). Current new data added are from 2010-2021. SD: standard deviation ; eGFR: estimated glomerular filtration rate; BMI, body mass index; IQR, interquartile range; TIA, transient ischemic attac; PAOD: peripheral arterial occlusive disease; CAD: coronary artery disease; ACE: angiotensin-converting enzyme; ARB: angiotensin – II receptor blocker

Patients preoperative medication prescription over time

Preoperative medication prescription from 2002-2021 are presented in Table 1. Statin use increased in both periods: 64,8% in 2002 through 2003, 82,1% in 2010 through 2011, 92,2% in 2020 through 2021 with mean statin use being higher in the 2010-12 cohort (83.3% vs 77.0%, <0.001). The use of beta-blockers and angiotensin-converting enzyme inhibitors did not differ over time in both periods. Angiotensin II antagonists usage was increased in period 2002-2011 but did not change between 2010-2021. Diuretics and anticoagulant use was not different over time for both periods. Mean anti-platelet usage was slightly higher in the 2002-2011 cohort when compared to the 2010-2021 cohort (88.9% vs 0.86.0%, p=0.021).

Patients carotid plaque composition

Plaque histology was performed on the collected atherosclerotic carotid plaques for the presence of the following plaque characteristics: lipid core >40%, intraplaque hemorrhage, collagen, macrophages, smooth muscle cells (SMC) and calcifications. Results were dichotomized as aforementioned. The % of patients having these plaque characteristic are summarized in Table 2. The percentage of patients with a lipid core >40% was significantly decreased in the period 2002-2011. In contrast, lipid core >40% was increased during the period 2010-2021. A similar pattern was also seen for other destabilizing plaque characteristics: intraplaque hemorrhage, macrophages and calcification with a decrease over time in the period 2002-2011 but now an increase over time in the period 2010-2021. On the other hand, for the stabilizing plaque characteristics, plaque collagen was not changed over time in the period 2002-2011 but showed a tendency of decreasing over time for the period 2010-2021. Smooth muscle cells are increasing over time for both the period 2002-2011 and 2010-2021.

Table 2. Presence of Atherosclerotic Plaque Components Over Time

Atherosclerotic Plaque Components	2002-2003 (n=250)	2004-2005 (n=408)	2006-2007 (n=352)	2008-2009 (n=332)	2010-2011 (n=318)	2012-2013 (n=317)	2014-2015 (n=238)	2016-2017 (n=150)	2018-2019 (n=133)	2020-2021 (n=121)	P value 2002-2010	p-value 2010-2021
Lipid core >40% of plaque, %	33.2	36.0	26.7	21.1	15.8	21.7	50.0	32.8	35.2	26.2	<0.001	<0.001
Intraplaque Hemorrhage, %	74.4	75.5	62.5	49.1	41.4	53.8	62.6	67.7	73.6	68.9	<0.001	<0.001
Collagen, %	73.6	85.8	80.1	76.8	79.0	79.4	67.4	66.7	81.2	70.5	0.643	0.111
Macrophages %	50.0	61.5	70.8	48.3	42.6	33.5	74.3	67.2	67.2	59.6	<0.001	<0.001
SMC %	64.8	74.4	71.1	72.8	69.0	52.0	48.6	57.9	62.3	77.0	<0.001	<0.001
Calcifications, %	51.6	62.0	60.5	51.0	24.9	23.4	26.7	39.1	46.7	36.1	<0.001	<0.001

Table 2. Presence of Atherosclerotic Plaque Components in patients undergoing CEA and included in the longitudinal biobank study Athero-Express 2002 – 2021. Data and p-values from 2002-2011 were as previously published by G.W. van Lammeren (Circulation, 2014). Current new data added are from 2010-2021. Percentage indicates the percentage of patients in the 2-year period that showed presence of: a lipid core >40%, intraplaque hemorrhage, collagen, macrophages, smooth muscle cells (SMC) and calcifications in plaque histology.

Change in semiquantitative plaque characteristics between 2010-2021

Having found changes for the presence of plaque characteristics over time in the new period 2010-2021, we investigated how semiquantitative information based on the degree of staining in 4 categories: No, Minor, Moderate and Heavy staining, was changing over time is this period (Figure 1). In the upper left plaques containing fat are increased. Plaques with no or minor staining of thrombus is low in most recent years in the upper right. Plaque with no or minor collagen or no or minor smooth muscle cell (SMC) staining did not change much (left middle and lower) in the last years while for macrophages (middle right) moderate and heavy staining were higher. For calcification the moderate and heavy staining was more often observed over time (lower right).

Figure 1. Semiquantitative plaque information based on the presence or degree of staining from 2010 to 2021 in 4 categories: No, Minor, Moderate and heavy staining.

Adjusted odds ratios for the presence of atherosclerotic plaque characteristics, per 2-year increase from 2010 to 2021

To explore if the changes over time remained after correction for confounders, we assessed the association between plaque characteristics and year of surgery (Figure 2) after adjustment for patient and procedural characteristics that changed over time (diabetes mellitus, eGFR, time between last event and surgery, symptoms, hypertension, history of CAD, statins use and antiplatelet drug use). After adjustment, all of the aforementioned plaque characteristics, except for smooth muscle cell and collagen content, remained significantly associated with year of surgery and indicated an increase in features that are considered to be associated with carotid plaque instability over time. Per 2-year increase, the adjusted odds ratios were: calcification 1,204 (95% confidence interval, 1,090-1,331; p<0,001), intraplaque hemorrhage 1,358 (95% confidence interval, 1,230-1,502; p<0,001); >40% fat in the plaque 1,271 (95% confidence interval, 1,150-1,407; p<0,001); macrophages 1,366 (95% confidence interval, 1,238-1,511; p<0,001). See figure 3 for histological sections of the aforementioned plaque characteristics.

Figure 2. Adjusted odds ratios for the presence of atherosclerotic plaque characteristics, per 2-year increase in time from 2010 to 2021. Odds ratios and *P* values were adjusted for diabetes mellitus, eGFR, time between last event and surgery, symptoms, hypertension, history of CAD, statins use and antiplatelet drug use.

Figure 3. Histological sections of adverse plaque characteristics. Upper left: heavy macrophage staining. Upper right: heavy calcification (arrow). Lower left: intraplaque hemorrhage (arrow). Lower right: >40% fat of plaque surface.

Carotid plaque composition in subgroups of patient with different symptoms at onset
Since plaques from asymptomatic patients have a more fibrous and less inflammatory phenotype as compared with patients with transient ischemic attack and stroke (19), we performed a sub-analysis on change of plaque characteristics over time in patients with different symptoms: asymptomatic, ocular symptoms, transient ischemic attack (TIA) or stroke (Table 4). This table shows for each patient subgroup the same significant increase of adverse plaque characteristics from 2010 to 2021 for: presence of a lipid core > 40%, intraplaque hemorrhage, macrophages. Calcifications changed significantly over time in the a-symptomatic and ocular group but did not change in the TIA and stroke patient group

Table 4. **Carotid Plaque Composition**

Plaque Composition	2010-2011 (n=318)	2012-2013 (n=317)	2014-2015 (n=238)	2016-2017 (n=150)	2018-2019 (n=133)	2020-2021 (n=121)	p-value 2010-2021
Asymptomatic patients	N=33	N=31	N=29	N=16	N=10	N=16	
Lipid core >40% of plaque %	0.0	30.4	35.7	27.3	33.3	18.2	0.002
Intraplaque hemorrhage %	21.9	55.6	38.5	90.9	55.6	63.6	0.001
Collagen in the plaque %	80.6	65.0	100.0	50.0	77.8	81.8	0.340
Macrophages in the plaque %	34.4	30.0	63.6	36.4	66.7	50.0	0.254
SMC in the plaque %	87.5	45.0	71.4	63.6	88.9	90.9	0.011
Calcifications in the plaque %	25.0	30.4	50.0	63.6	66.7	36.4	0.083
Patients with ocular symptoms	N=57	N=61	N=53	N=25	N=45	N=35	
Lipid core >40% of plaque %	7.0	14.3	59.4	26.1	31.8	14.3	<0.001
Intraplaque hemorrhage %	42.1	50.0	56.2	69.6	75.0	64.3	0.019
Collagen in the plaque %	78.9	89.5	42.9	100.0	82.5	78.6	0.023
Macrophages in the plaque %	33.3	15.8	71.0	65.2	65.9	64.3	<0.001
SMC in the plaque %	70.2	60.5	50.0	65.2	61.4	78.6	0.387
Calcifications in the plaque %	19.3	28.6	28.1	52.2	59.1	35.7	<0.001
TIA patients	N=130	N=124	N=85	N=55	N=45	N=35	
Lipid core >40% of plaque %	22.2	27.4	47.4	31.8	41.0	27.8	0.014
Intraplaque hemorrhage %	42.1	62.5	70.2	56.8	79.5	66.7	<0.001
Collagen in the plaque %	79.4	77.5	76.3	0.0	79.4	61.1	0.308
Macrophages in the plaque %	42.1	40.3	75.5	56.8	61.5	66.7	<0.001
SMC in the plaque %	68.3	45.7	49.1	65.1	59.0	72.2	0.017
Calcifications in the plaque %	25.6	22.6	17.5	31.8	35.9	33.3	0.316
Stroke patients	N=96	N=98	N=70	N=54	N=33	N=31	
Lipid core >40% of plaque %	17.2	17.9	51.1	38.0	33.3	37.5	<0.001
Intraplaque hemorrhage %	46.7	47.1	64.4	71.4	69.0	75.0	0.003
Collagen in the plaque %	79.6	81.2	57.7	66.7	82.8	62.5	0.010
Macrophages in the plaque %	50.5	37.7	77.8	84.0	76.7	46.2	<0.001
SMC in the plaque %	64.5	56.5	40.0	46.9	60.0	68.8	0.050
Calcifications in the plaque %	28.0	19.2	29.8	34.0	36.7	43.8	0.271

Table 4. Changes in atherosclerotic plaque components over time were divided according to the pre-operative symptoms: asymptomatic, ocular, transient ischemic attack (TIA) and stroke. Percentage indicates the percentage of patients in the 2-year period that showed presence of: a lipid core >40%, intraplaque hemorrhage, collagen, macrophages, smooth muscle cells (SMC) and calcifications in plaque histology.

Discussion

Although world-wide mortality of cardiovascular disease is increasing, Western-Europe prevalence remained unchanged and CVD mortality declined until 2013 together with an increase in hospital admission and CVD prescriptions. (11) Similarly, vulnerable plaque characteristics in human carotid plaques were decreasing between 2002-2011. (13) Time dependent changes in plaque characteristics in the last decade, however, are unknown. We now have investigated the plaque characteristics in the last decade in 1277 carotid endarterectomy (CEA) patients. This shows that vulnerable plaque characteristics like plaque content of macrophages, calcification, intraplaque hemorrhage and fat are increasing over time since 2010.

Patient characteristics over time
In the last decade the age of CEA patients did not increase while also the decline in smoking stabilized. The prevalence of diabetes showed a tendency towards increasing, as did patients in the SWEDEHEART registry (12) and in the male elderly Dutch population between 2010-2020 (20) which forms the majority of our patients studied. In the COVID19 year 2020-21, however, the % of diabetes patients is the lowest since 2002. Despite a tendency of an increase in diabetes, eGFR is increasing, suggesting that kidney function of these CEA patients is improving.

A major change is seen in the decrease in time between event and operation. This is expected as guidelines recommend that surgeons should strive to operate within 8 to 14 days after neurologic event. (21,22) It is, however, known that early after stroke and TIA, carotid plaques have a more unstable plaque phenotype but stabilize in the weeks after the event. (23) Next to a decrease in time between symptoms and surgery in 2010-2021, also the percentage of asymptomatic patients are lower while stroke patients are higher in the last decade.

Medication use showed that pre-operative statin use increased in both the 2002-2011 and 2010-2021 period. The increase in Angiotensin II antagonists in 2002-2011 is stabilized in the 2010-2021 period while antiplatelet was slightly lower in 2010-21. Other pre-operative medication use has not changed significantly. Although targeting the same pathways and pathologies, we have to realize that other specific medication prescriptions within the same drug entity might have been used in the last decade compared to 2002-2010, such as different beta-blockers, angiotensin-converting enzyme inhibitors, diuretics, antiplatelet and anticoagulants.

Plaque characteristics over time
This study shows time-dependent changes towards plaques with characteristics thought to be associated with plaque vulnerability. This seems to be in contrast with the decrease in mortality in Western Europe. (10) Around 23,000 strokes occur each year in the Netherlands and estimates indicate that the prevalence of stroke has risen over the past ten years(24). In our study, we also saw an increase of symptomatic patients in the last decade. TIA and stroke before carotid endarterectomy have been associated with a more vulnerable plaque phenotype compared to asymptomatic patients (7,8). The decrease in time to surgery and increase in symptomatic patients could be an explanation for the increase in plaque characteristics associated with vulnerability, however, the increase in vulnerable plaque characteristics remained significant after correction of these confounders. Next to this, subgroup analysis of plaque characteristics in the four different pre-operative symptom groups shows the same increase in vulnerable plaque characteristics in each of these groups.

Vulnerable plaque characteristics and cardiovascular events
The vulnerable plaque with a large atheroma, heavy macrophage deposition, covered by a thin fibrous cap was considered to be prone for rupture and defined as the thin-capped fibroatheroma (TCFA). (25) This concept is currently challenged (26), mainly since only a minority of TCFA plaques lead to

events. (2). Also in this study, we did not find any association between vulnerable plaque characteristics and cardiovascular events over time (suppl data S1). Of the vulnerable plaque characteristics of fat, calcification, macrophages and intraplaque hemorrhage (IPH) that significantly increased in time, only IPH has been previously associated with future cardiovascular events (1). Previously, the time associated decrease between 2002-2011 in plaque characteristics believed to be associated with plaque vulnerability including IPH, were also not associated with a reduced event rate in this cohort of CEA patients. (13) This is in line with previous studies suggesting a limited role of plaque characteristics in the occurrence of future cardiovascular events (1,2,26).

In the 2002-2011 study (13), the decrease in these vulnerable plaque characteristics coincided with an increase in statin use, suggesting statin use might be an explanation of a more stable plaque characteristics. Besides their primary lipid lowering effect, statins exert anti-inflammatory effects in cardiovascular patients. (27) The pleiotropic immune-modulatory properties of statins have gained much attention in the last decade as additional explanation of reduction in cardiovascular events. (28) In contrast, we now find more vulnerable plaque characteristics but find also a higher statin use in the 2010-2021 cohort as compared to the 2002-2010 cohort, suggesting that statin use is probably not the sole factor underlying time-dependent changes in plaque characteristics.

Limitations
This CEA cohort might not represent other CVD patients. Our observations may have been influenced by other cardiovascular risk factors as we do not have data on physical activity or additional drug use as only data on medication presented are available. Regarding limitations, bias in studying time-dependent trends might arise if, for instance, the disease diagnosis criteria have changed. In the Athero-Express study, we did not notice a reduction in the total number of patients. Nonetheless, we cannot rule out that the variations in our observations over time may be due to changes in patient characteristics and surgical indications that occurred during the same period.

Conclusion
In conclusion, we found that in the last decade carotid plaque characteristics associated with plaque vulnerability are increased in a large cohort of CEA patients. With a decrease in CVD mortality in Western-Europe as background these findings suggesting a limited role of histological plaque vulnerability in cardiovascular events.

References

1. Hellings WE, Peeters W, Moll FL, Piers SRD, van Setten J, Van der Spek PJ, et al. Composition of Carotid Atherosclerotic Plaque Is Associated With Cardiovascular Outcome. Circulation. 2010 May;121(17):1941–50.

2. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine. 2011 Jan 20;364(3):226–35.

3. Ihle-Hansen H, Vigen T, Berge T, Walle-Hansen MM, Hagberg G, Ihle-Hansen H, et al. Carotid Plaque Score for Stroke and Cardiovascular Risk Prediction in a Middle-Aged Cohort From the General Population. J Am Heart Assoc. 2023 Sep 5;12(17).

4. Gudmundsson EF, Björnsdottir G, Sigurdsson S, Andersen K, Thorsson B, Aspelund T, et al. Carotid plaque is strongly associated with coronary artery calcium and predicts incident coronary heart disease in a population-based cohort. Atherosclerosis. 2022 Apr 1;346:117–23.

5. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis. Atherosclerosis. 2012 Jan;220(1):128–33.

6. Hellings WE. Atherosclerotic Plaque Composition and Occurrence of Restenosis After Carotid Endarterectomy. JAMA [Internet]. 2008 Feb 6;299(5):547. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.299.5.547

7. Holdsworth RJ, Mccollum PT, Bryce JS, Harrison DK. Symptoms, Stenosis and Carotid Plaque Morphology. Is Plaque Morphology Relevant? Vol. 9, Eur J Vasc Endovasc Surg. 1995.

8. Schindler A, Schinner R, Altaf N, Hosseini AA, Simpson RJ, Esposito-Bauer L, et al. Prediction of Stroke Risk by Detection of Hemorrhage in Carotid Plaques: Meta-Analysis of Individual Patient Data. JACC Cardiovasc Imaging. 2020 Feb 1;13(2):395–406.

9. van Dam-Nolen DHK, Truijman MTB, van der Kolk AG, Liem MI, Schreuder FHBM, Boersma E, et al. Carotid Plaque Characteristics Predict Recurrent Ischemic Stroke and TIA: The PARISK (Plaque At RISK) Study. JACC Cardiovasc Imaging. 2022 Oct 1;15(10):1715–26.

10. Li Y, Cao GY, Jing WZ, Liu J, Liu M. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990−2019: findings from 2019 global burden of disease study. Eur J Prev Cardiol. 2023 Feb 1;30(3):276–86.

11. Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N. Trends in the epidemiology of cardiovascular disease in the UK. Vol. 102, Heart. BMJ Publishing Group; 2016. p. 1945–52.

12. Leosdottir M, Hagstrom E, Hadziosmanovic N, Norhammar A, Lindahl B, Hambraeus K, et al. Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive

medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006-2019: a registry-based cohort study. BMJ Open. 2023 May 12;13(5).

13. Van Lammeren GW, Den Ruijter HM, Vrijenhoek JEP, Van Der Laan SW, Velema E, De Vries JPPM, et al. Time-dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery. Circulation. 2014 Jun 3;129(22):2269–76.

14. Verhoeven BAN, Velema E, Schoneveld AH, De Vries JPPM, De Bruin P, Seldenrijk CA, et al. Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol. 2004;19(12).

15. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomised controlled trial. The Lancet. 2004 May 8;363(9420):1491–502.

16. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). The Lancet [Internet]. 1998;351(9113):1379–87. Available from: https://www.sciencedirect.com/science/article/pii/S0140673697092921

17. Hellings WE, Pasterkamp G, Vollebregt A, Seldenrijk CA, De Vries JPPM, Velema E, et al. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. J Vasc Surg. 2007 Dec;46(6):1147–54.

18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Annals of Internal Medicine A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation [Internet]. Vol. 130. 1999. Available from: https://annals.org

19. Verhoeven B, Hellings WE, Moll FL, de Vries JP, de Kleijn DPV, de Bruin P, et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg. 2005 Dec;42(6):1075–81.

20. Overbeek JA, Nijpels G, Swart KMA, Blom MT, Elders PJM, Herings RMC. Type 2 Diabetes, the Epidemic: Trends in Prevalence and Incidence, 2004-2020. Diabetes, Metabolic Syndrome and Obesity. 2024;17:1503–9.

21. Tanious A, Pothof AB, Boitano LT, Pendleton AA, Wang LJ, de Borst GJ, et al. Timing of Carotid Endarterectomy After Stroke: Retrospective Review of Prospectively Collected National Database. Ann Surg. 2018 Sep 1;268(3):449–56.

22. Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al. Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. European Journal of Vascular and Endovascular Surgery. 2023 Jan 1;65(1):7–111.

23.   Peeters W, Hellings WE, De Kleijn DPV, De Vries JPPM, Moll FL, Vink A, et al. Carotid atherosclerotic plaques stabilize after stroke insights into the natural process of atherosclerotic plaque stabilization. Arterioscler Thromb Vasc Biol. 2009;29(1):128–33.

24.   Global Burden of Disease Collaborative Network. 2019. Global Burden of Disease Results Tool. [Internet]. [cited 2024 Aug 22]. Available from: https://ghdx.healthdata.org/gbd-2019

25.   Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. In: European Heart Journal. 2004. p. 1077–82.

26.   Libby P, Pasterkamp G. Requiem for the "vulnerable plaque." Vol. 36, European Heart Journal. Oxford University Press; 2015. p. 2984–7.

27.   Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Curr Cardiol Rev. 2017 May 2;13(3).

28.   Arnaud C, Braunersreuther V, Mach F. Toward Immunomodulatory and Anti-Inflammatory Properties of Statins. Trends Cardiovasc Med [Internet]. 2005;15(6):202–6. Available from: https://www.sciencedirect.com/science/article/pii/S1050173805001210